Drug holiday in patients with polycystic liver disease treated with somatostatin analogues
Background: Somatostatin analogues (SAs) reduce liver volume and relief symptoms in polycystic liver disease (PLD). Its effect wears off after continuing therapy suggesting development of SA tolerance in patients on chronic therapy. We postulate that a drug holiday resensitizes the liver to its acut...
Main Authors: | René M. M. van Aerts, Marieke Kolkman, Wietske Kievit, Tom J. G. Gevers, Frederik Nevens, Joost P. H. Drenth |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-10-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756284818804784 |
Similar Items
-
Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease
by: Gevers Tom JG, et al.
Published: (2012-04-01) -
Studies on the intestinal absorption of somatostatin analogues
by: Bell, J. M.
Published: (1987) -
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
by: Ström T, et al.
Published: (2019-10-01) -
Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease.
by: Manoe J Janssen, et al.
Published: (2012-01-01) -
Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
by: Basma Haris, et al.
Published: (2020-12-01)